Therapy-related malignancies following treatment of germ cell cancer

International Journal of Cancer

Volumn 83, Issue 6, 1999, Pages 860-863

  Kollmannsberger, Christian ^a   Hartmann, Jörg T ^a   Kanz, Lothar ^a   Bokemeyer, Carsten ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CISPLATIN; ETOPOSIDE; GYRASE INHIBITOR; IFOSFAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER RISK; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; GERM CELL TUMOR; HUMAN; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SECOND CANCER;

ANTINEOPLASTIC AGENTS; GERMINOMA; HUMANS; LEUKEMIA; MALE; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 0032736109     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991210)83:6<860::AID-IJC32>3.0.CO;2-L     Document Type: Conference Paper

References (29)

1. ANDERSEN, M.K., JOHANSSON, B., LARSEN, S.O. and PEDERSEN-BJERGAARD, J., Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica, 83, 483-488 (1998).
2. BAJORIN, D.F., MOTZER, R.J., RODRIGUEZ, E., MURPHY, B. and BOSL, G.J., Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J. nat. Cancer Inst., 85, 60-62 (1993).
3. BEN-YEHUDA, D. and 13 OTHERS, Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 11, 4296-4303 (1996).
4. BOKEMEYER, C., FREUND, M., SCHMOLL, H.J., RIEDER, H. and FONATSCH, C., Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour. Ann. Oncol., 3, 772 (1992).
5. BOKEMEYER, C. and 24 OTHERS, The use dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. Semin. Oncol., 25, 24-32 (1998).
6. BOKEMEYER, C., KOLLMANNSBERGER, C., MEISNER, C., HARSTRICK, A., BEYER, J., METZNER, B., HARTMANN, J.T., SCHMOLL, H.J., EINHORN, L.H., KANZ, L. and NICHOLS, C.R., First-line high-dose chemotherapy (HD-CT) versus standard-dose PEB/PE1 (SD-CT) in patients (pts) with advanced germ cell tumors (GCT). A matched pair analysis. Proc. Amer. Soc. clin. Oncol., 18, 309a (1999).
7. BOKEMEYER, C. and SCHMOLL, H.J., Secondary neoplasms following treatment of malignant germ cell tumors. J. clin. Oncol., 11, 1703-1709 (1993).
8. BOKEMEYER, C. and SCHMOLL, H.J., Treatment of testicular cancer and the development of secondary malignancies. J. clin. Oncol., 13, 283-292 (1995).
9. BOKEMEYER, C., SCHMOLL, H.J., KUCZYK, M.A., BEYER, J. and SIEGERT, W., Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J. nat. Cancer Inst., 87, 58-60 (1995).
10. BOSHOFF, C., BEGENT, R.H., OLIVER, R.T., RUSTIN, G.J., NEWLANDS, E.S., ANDREWS, R., SKELTON, M., HOLDEN, L. and ONG, J., Secondary tumours following etoposide containing therapy for germ cell cancer. Ann. Oncol., 6, 35-40 (1995).
11. FELIX, C.A., WALKER, A.M., LANGE, P.H., WILLIAMS, T.M., WINICK, N.J., CHEUNG, N.-K.V., LOVETT, B.D., NOWELL, P.C., BLAIR, I.A. and RRBBECK, T.R., Association of CYP3A4 genotype with treatment-related leukemia. Proc. nat. Acad. Sci. (Wash.), 95, 13176-13181 (1998).
12. HENTRICH, M., BRACK, N. and HARTENSTEIN, R., Secondary acute promyelocytic leukemia following etoposide containing chemotherapy for germ cell tumors (GCT). Proc. Amer. Soc. clin. Oncol., 17, 333a (1998).
13. KARP, J.E. and SMITH, M.A., The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations of treatment and prevention. Semin. Oncol., 24, 103-113 (1997).
14. KOLLMANNSBERGER, C., BEYER, J., DROZ, J.P., HARSTRICK, A., HARTMANN, J.T., BIRON, P., FLÉCHON, A., SCHÖFFSKI, P., KUCZYK, M.A., SCHMOLL, H.J. and BOKEMEYER, C., Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J. clin. Oncol., 16, 3386-3391 (1998a).
15. KOLLMANNSBERGER, C. HARTMANN, J.T., KANZ, L. and BOKEMEYER, C., Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with autologuos stem cell support in patients with potentially curable malignancies. J. Cancer Res. clin. Oncol., 124, 207-214(1998b).
16. NICHOLS, C.R., BREEDEN, E.S., LLOEHRER, P.J., WILLIAMS, S.D. and EINHORN, L.H., Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. nat. Cancer Inst., 85, 36-40 (1993).
17. NICHOLS, C.R., ROTH, B.J., HEEREMA, N., GRIEP, J. and TRICOT, G., Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N. Engl. J. Med., 322, 1425-1429 (1990).
18. PEDERSEN-BJERGAARD, J., DAUGAARD, G., HANSEN, S.W., PHILIP, P., LARSEN, S.O. and RORTH, M., Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ cell tumors. Lancet, 338, 359-363 (1991).
19. PEDERSEN-BJERGAARD, J., PHILIP, P., LARSEN, S.O., JENSEN, G. and BYRSTING, K., Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood, 76, 1083-1091 (1990).
20. PUI, C.-H., RIBEIRO, R.C., HANCOCK, M.L., RIVERA, G.K., EVANS, W.E., RAIMONDI, S.C., HEAD, D.R., BEHM, F.E., MAHMOUD, M.H., SANDLUND, J.T. and CHRIST, W.M., Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N. Engl. J. Med., 325, 1682-1687 (1991).
21. RATAIN, M.J. and ROWLEY, J.D., Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann. Oncol., 3, 107-111 (1992).
22. ROTH, B.J., GREIST, A., KUBILIS, P.S., WILLIAMS, S.D. and EINHORN, L.H., Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J. clin. Oncol., 6, 1239-1247 (1988).
23. SMITH, M.A. and 12 OTHERS, Secondary leukemia and myelodysplastic syndrome after treatment with epipodophyllotoxins. J. clin. Oncol., 17, 569-577 (1999).
24. TRAVIS, L.B. and 17 OTHERS, Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. nat. Cancer Inst., 89, 1429-1439 (1997).
25. TRAVIS, L.B., HOLOWATY, E., BERGFELDT, K., LYNCH, C.F., KOHLER, B.A., WIKLUND, T., CURTIS, R.E., HALL, P., ANDERSSON, M., PUKKALA, E., STURGEON, J. and STOVALL, M., Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N. Engl. J. Med., 340, 351-357 (1999).
26. VAN LEEUWEN, F.E., STIGGELBOUT, A.M., VAN DEN BELT-DUSEBOUT, A.W., NOYON, R., ELIEL, M.R., VAN KERKHOFF, E.H., DELEMARRE, J.F. and SOMERS, R., Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J. clin. Oncol., 11, 415-424 (1993).
27. VON DER MAASE, H., SPECHT, L., JACOBSON, G.K. and ET, A., Surveillance following orchiectomy for stage I seminoma of the testis. Europ. J. Cancer, 29, 1931-1934 (1993).
28. WHITLOCK, J.A., GREER, J.P. and LUKENS, J.N., Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemia. Cancer, 68, 600-604 (1991).
29. WILLIAMS, S.D., BIRCH, R., EINHORN, L.H., IRWIN, L., GRECO, F.A. and LOEHRER, P.J., Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435-1440 (1987).